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For many years pasteurization has been recommended for rendering milk safe for human consumption.
Two methods were employed in the past. The 'holder method' which entails holding the milk for thirty minutes at a temperature between 63'C and 66°C. The 'high temperature short time' method necessitates heating the milk to 72°C for fifteen seconds.
Experiments using the Southern cross sterilizer cooler have shown that setting the sterilizer for a holding time of five minutes ensures that the feeds are kept at a temperature of 72°C or higher for four minutes for an 8 oz feed and five minutes for a 2 oz feed. At this temperature/time combination the following organisms were destroyed: Each sample was divided in 24 parts and each part examined separately to increase the sensitivity of the test. Spore-bearing organisms were not entirely removed but the numbers were greatly reduced, to a figure of 25 per ml or less. This has been accepted by the American Pediatric Association as a safe limit. It has also been shown by American workers that the temperatures involved do not appreciably damage various heatlabile nutrients which are present in milk.
The makers of the Southern Cross sterilizer cooler recommend a holding time of twenty-five minutes which makes the complete cycle about fifty minutes. Our In 1959 Pool reported that if fresh frozen plasma is thawed slowly some insoluble material was present which dissolved on warming to 37°C and that this material contained much of the anti-hwmophilic globulin (AHG). She has now reported (Pool 1965) the successful use of this method of preparing AHG concentrate and its use for the treatment of hemophilia. The production of this concentrate in Portsmouth and its use will be briefly reported.
With a single four-bucket refrigerated centrifuge we can process up to twenty pints of blood a day. The donors are bled into double Fenwall packs containing ACD mixture; the packs are cooled and centrifuged at 4°C as soon as possible. The plasma is expressed into the second pack and this is then immersed in powdered solid carbon dioxide, while the first pack, now containing packed red cells, is maintained at 4°C. When the plasma is frozen solid the two packs are transferred to a 4°C refrigerator. Next day the plasma has thawed and contains the 'cryoglobulin' precipitate. The plasma (and the red cell pack) is centrifuged and then the plasma is returned to the red cells leaving the cryoglobulin in the plasma pack which is now separated from the red cell pack. The cryoglobulin packs are stored at -20°C; for use they are slowly warmed to 37°C, and with gentle kneading the cryoglobulin dissolves in the 5-10 ml of plasma left in the pack. The warm cryoglobulin from a sufficient number of packs is aspirated into a disposable 20 or 50 ml syringe and injected intravenously into the patient. The ABO blood group antigens and antibodies are ignored. Since the concentrate may contain some small amount of red cell material, only Rh-negative concentrate is given to Rh-negative patients.
Results
The AHG concentration in the dissolved concentrate and in the patients before, immediately after and some time after injection was estimated using the method of Biggs and Macfarlane. Analysis of several samples of cryoglobulin showed that on average about 50 % of the AHG in the original blood was present in the concentrate and that the concentration was fiftyfold. Table 1 summarizes the results of a number of treatments. The immediate post-injection level is about the level which would have been expected if half the number of units in fact given had been given as pints of fresh blood. The AHG levels from twelve to twenty-two hours after the injections show that the survival of the injected AHG is as good as with other forms of AHG therapy. The clinical response in each case was satisfactory with prompt cessation in bleeding, even though in these initial studies the levels of AHG achieved were sometimes rather less than perhaps would have been ideal (due to inadequate dosage).
Summary and Conclusion
About half the anti-himophilic globulin in a pint of fresh blood can be concentrated into 5 ml and stored for at least six months with no loss of potency. Thus the concentrate from ten pints of blood can be given with a 50 ml syringe and is as effective as about 3-4 pints of fresh frozen plasma of average potency. This method has four great advantages: (1) Treatment is by syringe and not by transfusion.
(2) The concentrate has a long 'shelf life' at -200C. (3) The red cells and platelets and the rest of the plasma is used for other patients so there is no waste. (4) The concentrate can be prepared with no special equipment or expertise and sterility presents no problems in this closed system.
In the opinion of the author this concentrate is ideal for all hmmophilic therapy, except possibly for major therapy which may need animal AHG, and it should be available in every centre undertaking treatment of this distressing condition, unless or until other more highly concentrated preparations become available.
